NEXALIN TECHNOLOGY IN

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3

28 5 2025 07:00:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data

13 5 2025 05:30:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

06 5 2025 11:40:23 提供 Nasdaq GlobeNewswire

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

05 5 2025 05:20:19 提供 Nasdaq GlobeNewswire

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

01 5 2025 07:30:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

24 4 2025 06:00:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

23 4 2025 06:15:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

21 4 2025 05:00:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

14 4 2025 09:30:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

02 4 2025 05:30:00 提供 Nasdaq GlobeNewswire

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3

26 3 2025 05:30:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

03 3 2025 05:30:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval

28 2 2025 05:30:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

26 2 2025 05:30:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

18 2 2025 05:30:00 提供 Nasdaq GlobeNewswire

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

10 2 2025 06:00:00 提供 Nasdaq GlobeNewswire

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

03 2 2025 05:30:00 提供 Nasdaq GlobeNewswire

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

23 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025

14 1 2025 05:30:00 提供 Nasdaq GlobeNewswire

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

23 12 2024 07:00:00 提供 Nasdaq GlobeNewswire